RUNIMOTAMAB

UNII:	F8Z9VSZ0K1
Type:	INGREDIENT SUBSTANCE
Formula:
Preferred Substance Name:	RUNIMOTAMAB
GSRS Full Record:	F8Z9VSZ0K1 i

2361325-98-4
ANTI-HER2/CD3 TDB
BTRC-4017A
BTRC4017A
HER2/CD3 TDB
IMMUNOGLOBULIN G1 (300-GLYCINE,369-TRYPTOPHAN), ANTI-(HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR HER2) (HUMAN MONOCLONAL KTRC5520 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL KTRC5520 .KAPPA.-CHAIN, (229->228'),(232->231')-BIS(DISULFIDE) WITH IMMUNOGLOBULIN G1 (299-GLYCINE,368-SERINE,370-ALANINE,409-VALINE) ANTI-(HUMAN CD3 ANTIGEN) (HUMAN MONOCLONAL HTHR4765 .GAMMA.1-CHAIN) DISULFIDE WITH HUMAN MONOCLONAL HTHR4765 .KAPPA.-CHAIN
IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINE PROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185CERBB2, NEU, CD340)) AND ANTI-(HOMO SAPIENS CD3E (CD3 EPSILON, LEU-4)), MONOCLONAL ANTIBODY, BISPECIFIC; GAMMA1 HEAVY CHAIN ANTI- ERBB2 (1-450) (VH ANTI-ERBB2 (HOMO SAPIENS IGHV3-66*01 (81.6%)- (IGHD)-IGHJ4*01 (100%)) CDR-IMGT (8.8.13) (26-33.51-58.97-109) (1-120)- HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1, G1V30 CH2 G84.4, G1V32 CH3 W22 (CH1 R120>K (217) (121-218), HINGE 1-15 (219-233), CH2 N84.4>G (300) (234-343), CH3 E12 (359), M14 (361), T22>W (369) (344- 448), CHS (449-450)) (121-450)), (223-214')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI-ERBB2 (1'-214') (V-KAPPA ANTI-ERBB2 (HOMO SAPIENS IGKV1-39*01 (86.3%)-IGKJ1*01 (100%)) CDR-IMGT (6.3.9) (27-32.50-52.89-97) (1'-107')- HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (153), V101 (191) (108'-214')); GAMMA1 HEAVY CHAIN ANTI-CD3E (1''-449'') (VH ANTI-CD3E (MUS MUSCULUS IGHV1-66*01 (82.7%)-(IGHD)-IGHJ2*01 (86.7%)/HOMO SAPIENS ANTI-CD3E IGHV1-3*01 (82.7%)-(IGHD)-IGHJ4*01 (100%)) CDR-IMGT (8.8.12) (26- 33.51-58.97-108) (1''-119'')-HOMO SAPIENS IGHG1*03V, G1M3>G1M17, NG1M1, G1V30 CH2 G84.4, G1V33 CH3 S22, A24, V86 (CH1 R120>K (216) (120''-217''), HINGE 1-15 (218''-232''), CH2 N84.4>G (299) (233-342), CH3 E12 (358), M14 (360), T22>S (368), L24>A (370), Y86>V (409) (343''-447''), CHS (448''-449'') (120''-449'')), (222''-219''')-DISULFIDE WITH KAPPA LIGHT CHAIN ANTI- CD3E (1'''-219''') (V-KAPPA ANTI-CD3E (HOMO SAPIENS IGKV4-1*01 (91.8%)- IGKJ1*01 (100%)) CDR-IMGT (12.3.8) (27-38.56-58.95-102) (1'''-112''')-HOMO SAPIENS IGKC*01 (100%), KM3 A45.1 (158), V101 (196) (113'''-219''')); DIMER (229-228'':232-231'')-BISDISULFIDE, PRODUCED IN CHINESE HAMSTER OVARY (CHO) CELLS, NON-GLYCOSYLATED
RG-6194
RO-7227780
RO7227780
RUNIMOTAMAB [USAN]
Runimotamab [WHO-DD]
runimotamab [INN]

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

RUNIMOTAMAB

Synonyms and Mappings

Resources